Administration of the SGLT2 inhibitor, DWP16001, can be an adjunctive method for managing diabetes in terms of glycaemic control without adverse effects in diabetic dogs receiving insulin therapy. This evidence concerns the gene SLC5A2 and diabetes mellitus.